Nordic Bioscience Targets 20% SDV with Risk-Based Monitoring to Streamline Clinical Trial Execution
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
This case study shows how Nordic Bioscience, one of Europe’s fastest-growing biotech companies, focused site monitoring efforts with only 20% source document verification (SDV) to improve study data quality.
For further education on achieving reduced SDV and site monitoring costs with a risk-based approach, register for Medidata's upcoming seminar taking place in Stuttgart, Germany on 23 October.